Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 13

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

300

HTML

2388

Figures (1-6)

194

Sum=2882

Jul 1, 2004 (publication date) through Jul 17, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jul 1, 2004; 10(13): 1867-1871
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1867

Full Size Figure Download Figure

Figure 6 Pathological changes of liver 1 wk after 6 wk of treatment with Ad/hEndo (HE, original magnification: × 200).

Citation: Li L, Huang JL, Liu QC, Wu PH, Liu RY, Zeng YX, Huang WL. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J Gastroenterol 2004; 10(13): 1867-1871
URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1867.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1867